MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
insight
/
details

Genomic Medicine’s Impact on Mitochondrial Diseases: Unraveling Complexity and Paving the Way for Precision Healthcare

NextEdge Admin

14 Mar 2024

3 min 30 sec

Mitochondrial diseases are primarily caused by genetic mutations affecting the mitochondrial DNA (mtDNA) or nuclear DNA (nDNA), which encode proteins essential for mitochondrial function. These mutations disrupt oxidative phosphorylation (OXPHOS), the process responsible for generating adenosine triphosphate (ATP), the cell’s main energy source. The clinical spectrum is vast, involving organs with high ATP dependence, making diagnosis complex.

Mitochondrial diseases display unique inheritance patterns. Maternal inheritance is prevalent, with mitochondrial DNA (mtDNA) passed from mother to offspring. Heteroplasmy, the coexistence of normal and mutated mtDNA, contributes to varied disease severity among individuals and tissues. Autosomal inheritance of nuclear gene mutations also plays a role, following Mendelian patterns. Mitochondrial diseases often exhibit a threshold effect, where a critical level of mutated mtDNA triggers clinical symptoms. Genomic medicine has played a transformative role in understanding and addressing mitochondrial diseases. This comprehensive approach provides insights into both nuclear and mtDNA, offering a more accurate and detailed understanding of mitochondrial disorders.

The emerging connections between genetic variants in mitochondrial genes and drug-induced side effects highlight the importance of incorporating mitochondrial genetics into drug prescribing decisions.

As our understanding of mitochondrial genetics deepens, gene therapy emerges as a potential avenue for treating mitochondrial disorders, offering tailored solutions based on individual patients’ genetic profiles. Gene therapy offers hope for those with Leber Hereditary Optic Neuropathy (LHON), a mitochondrial disorder causing vision loss. LHON is linked to specific mutations in mitochondrial DNA. Recent breakthroughs in gene therapy aim to address these mutations, potentially restoring mitochondrial function and halting vision deterioration. Clinical trials are underway, showcasing the promising role of gene therapy in treating LHON by targeting the root cause at the genetic level. While challenges persist, these advancements signify a significant step toward personalized treatments for mitochondrial disorders, bringing optimism to those affected by LHON.

In conclusion, mitochondrial diseases present a complex landscape, but genomic medicine, especially with advancements in genetic testing, is paving the way for more precise diagnosis and targeted therapeutic interventions. Continued research and technological progress hold the key to unlocking new therapeutic strategies, ushering in a transformative era in the management of mitochondrial disorders.